Artiva Biotherapeutics Business Summary

Artiva Biotherapeutics, Inc. (ARTV) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, collaboration milestones, and development support for its allogeneic cell therapy platform. The company’s business model is centered on the development of "off-the-shelf," cryopreserved natural killer (NK) cell therapies, which are designed to be more accessible and cost-effective than traditional patient-derived CAR-T treatments. Artiva operates through two primary therapeutic segments: autoimmune diseases, led by its flagship candidate AlloNK (AB-101) for conditions like refractory rheumatoid arthritis and lupus nephritis, and oncology, focusing on B-cell malignancies and solid tumors. In the competitive landscape of next-generation cell therapy, Artiva contends with firms such as Fate Therapeutics, Nkarta, Allogene Therapeutics, and Rocket Pharmaceuticals. The company distinguishes itself by leveraging a large-scale manufacturing process that enables outpatient, community-based administration, positioning it as a leader in scalable, biologics-like immunotherapy. Artiva was founded in 2019 as a U.S.-based spin-out of South Korea’s GC Cell (formerly GC LabCell), with a founding team that included former CEO Tom Farrell and co-founder Peter Flynn. The current leadership is led by President and CEO Fred Aslan, M.D., a former investor at Venrock and executive at Vividion Therapeutics with an M.D. from Yale and an MBA from Harvard. In February 2026, the company strengthened its executive suite by appointing Thad Huston, previously of Galapagos and Kite Pharma, as Chief Financial Officer. Other key leaders include Chief Medical Officer Subhashis Banerjee, M.D., Chief Operating Officer Jennifer Bush, and Chief Technical Operations Officer Christopher Horan. Artiva is backed by a high-pedigree investor base including Venrock, 5AM Ventures, RA Capital Management, and RTW Investments, and recently expanded its board with the appointment of biopharma veteran Elaine Sorg in early 2026.